1. Yamashita S, Takeshima H, Matsumoto F, Yamasaki K, Fukushima T, Sakoda H, Nakazato M, Saito K, Mizoguchi A, Watanabe T, Ohta H, Yokogami K.: Detection of the KIAA1549-BRAF fusion gene in cells forming microvascular proliferations in pilocytic astrocytoma. PLoS ONE, 2019,14 (7): e0220146 doi: 10.1371/journal.pone.0220146.
2. Nishida T, Tsubouchi H, Hamada T, Imamura N, Hiyoshi M, Yano K, Kangawa K, Nakazato M, Nanashima A. Plasma desacyl ghrelin-to-acyl ghrelin ratio is a predictor of postoperative complications and prognosis after pancreaticoduodenectomy. Oncol Lett. 2019, 18(5):4974-4983. doi: 10.3892/ol.2019.10821.
3. Kim S, Bolatkan A, Kaneko S, Ikawa N, Asada K, Komatsu M, Hayami S, Ojima H, Abe N, Yamaue H, Hamamoto R. Deregulation of the Histone Lysine-Specific Demethylase 1 Is Involved in Human Hepatocellular Carcinoma. Biomolecules. 2019, 9(12) E810. doi: 10.3390/biom9120810.
4. Takeuchi A, Yokoyama S, Nakamori M, Nakamura M, Ojima T, Yamaguchi S, Mitani Y, Shively JE, Yamaue H. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Sci Rep. 2019, 9(1):12702. doi: 10.1038/s41598-019-49230-w.
5. Zhang W, Sakoda H, Nakazato M.: Neuromedin U suppresses insulin secretion by triggering mitochondrial dysfunction and endoplasmic reticulum stress in pancreatic β-cells. FASEB J. 2020, 34: 133-147 doi: 10.1096/fj.201901743R.
6. Islam MN, MitaY, Maruyama K, Tanida R, Zhang W, Sakoda H, Nakazato M.: Liver-expressed antimicrobial peptide 2 antagonizes the effect of ghrelin in rodents. J Endocrinol. 2020, 244(1):13-23. doi: 10.1530/JOE-19-0102.
7. Nakazato Y, Fujita Y, Nakazato M, Yamashita T. Neurons promote encephalitogenic CD4+ lymphocyte infiltration in experimental autoimmune encephalomyelitis. Sci Rep. 2020, 10(1):7354. doi: 10.1038/s41598-020-64363-z.
8. Fujita M, Yamaguchi R, Hasegawa T, Shimada S, Arihiro K, Hayashi S, Maejima K, Nakano K, Fujimoto A, Ono A, Aikata H, Ueno M, Hayami S, Tanaka H, Miyano S, Yamaue H, Chayama K, Kakimi K, Tanaka S, Imoto S, Nakagawa H. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020, 53:102659.
9. Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 2020, doi: 10.1111/cas.14363.
10. Mizumoto Y, Hemmi H, Katsuda M, Miyazawa M, Kitahata Y, Miyamoto A, Nakamori M, Ojima T, Matsuda K, Nakamura M, Hayata K, Fukuda-Ohta Y, Sugiyama M, Ohta T, Orimo T, Okura S, Sasaki I, Tamada K, Yamaue H, Kaisho T. Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade. Br J Cancer. 2020, doi: 10.1038/s41416-020-0757-2.